Beam Therapeutics reported promising efficacy in November for the first four sickle cell disease (SCD) patients treated with its base edited cell therapy BEAM-101 in the ongoing Phase I/II BEACON clinical trial, despite one death associated with busulfan conditioning used to prepare patients for treatment. In data reported on 8 December at the American Society of Hematology (ASH) annual meeting in San Diego, efficacy seen in three more patients was consistent with the first four, without another major busulfan-related event.
Key Takeaways
- Beam Therapeutics’ base-edited cell therapy BEAM-101 showed consistent efficacy in additional sickle cell patients treated in the Phase I/II BEACON trial relative to a prior update.
Respiratory adverse events, such as the idiopathic pneumonia syndrome that resulted in the death of the BEACON trial participant, are...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
